EP0973544A1 - Immunotolerant prothrombin complex preparation - Google Patents
Immunotolerant prothrombin complex preparationInfo
- Publication number
- EP0973544A1 EP0973544A1 EP98913425A EP98913425A EP0973544A1 EP 0973544 A1 EP0973544 A1 EP 0973544A1 EP 98913425 A EP98913425 A EP 98913425A EP 98913425 A EP98913425 A EP 98913425A EP 0973544 A1 EP0973544 A1 EP 0973544A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- plasma
- factor viii
- factors
- factor
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- 108010094028 Prothrombin Proteins 0.000 title claims abstract description 31
- 102100027378 Prothrombin Human genes 0.000 title claims abstract description 30
- 229940039716 prothrombin Drugs 0.000 title claims abstract description 30
- 230000006057 immunotolerant effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 4
- 108010054218 Factor VIII Proteins 0.000 claims description 49
- 102000001690 Factor VIII Human genes 0.000 claims description 49
- 229960000301 factor viii Drugs 0.000 claims description 49
- 239000003599 detergent Substances 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 18
- 239000012876 carrier material Substances 0.000 claims description 17
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 230000000415 inactivating effect Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 229940124135 Factor VIII inhibitor Drugs 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 230000000779 depleting effect Effects 0.000 claims description 4
- 238000001728 nano-filtration Methods 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 210000000605 viral structure Anatomy 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 239000011780 sodium chloride Substances 0.000 description 25
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 23
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- 244000052769 pathogen Species 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 239000012620 biological material Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 239000013043 chemical agent Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 230000002779 inactivation Effects 0.000 description 10
- 108010054265 Factor VIIa Proteins 0.000 description 9
- 229920005654 Sephadex Polymers 0.000 description 9
- 239000012507 Sephadex™ Substances 0.000 description 9
- 229960000182 blood factors Drugs 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229940012414 factor viia Drugs 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 102100023804 Coagulation factor VII Human genes 0.000 description 7
- 108010023321 Factor VII Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229940012413 factor vii Drugs 0.000 description 7
- 108010047303 von Willebrand Factor Proteins 0.000 description 7
- 102100036537 von Willebrand factor Human genes 0.000 description 7
- 208000009292 Hemophilia A Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- 238000011097 chromatography purification Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229960001134 von willebrand factor Drugs 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100022641 Coagulation factor IX Human genes 0.000 description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 description 4
- 108010076282 Factor IX Proteins 0.000 description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960004222 factor ix Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- -1 fatty acid esters Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 101001022148 Homo sapiens Furin Proteins 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 102000029301 Protein S Human genes 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 108010025221 plasma protein Z Proteins 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000012541 Fractogel® Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LQSDVRPFRAWMKF-UHFFFAOYSA-N ethanol methanol propan-2-one hydrate Chemical compound O.OC.CCO.CC(C)=O LQSDVRPFRAWMKF-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- the invention relates to a pharmaceutical composition for the treatment of blood coagulation disorders, in particular factor VIII inhibitor patients.
- the invention further relates to a method for producing such a composition and the use thereof.
- Blood coagulation is triggered by a series of successive reactions of various proteins or enzymes.
- a lack of blood coagulation factors prevents the formation of fibrin from fibrinogen and thus the closure of the wound; the result is bleeding.
- Hemophilia A is one such case. This is the most common bleeding disorder and is caused by the lack of factor VIII.
- Preparations containing factor VIII are used for the substitution treatment of hemophilia A. Treatment with these preparations leads to rapid hemostasis in most cases.
- a plasma fraction containing a mixture of coagulation factors are currently offered for the treatment of factor VIII inhibitor patients.
- This plasma fraction can contain, for example, the factors of the prothrombin complex (Factors II, VII, IX and X).
- a blood coagulation-demanding preparation with factor VIII inhibitor bypass activity (FEIBA ® TIM 4, Fa. IMMUNO AG), the AT-B 0,368,883, for example, obtained according by treatment of cryosupernatant.
- This preparation also contains coagulation factors II, VII, IX and X.
- the effect of a FEIBA preparation is complex due to its complex composition.
- Mariani et al. Thrombosis Res. 31, 475-488 (1983)
- factor VII names factor VII in its activated form as an active principle. It was found that after infusion of a FEIBA preparation there is an increased content of factor VIII in the plasma of hemophiles.
- Teitel Thrombosis and Haemostasis 66 (5) 559-564, (1991) also discusses the role of factor VIIa in prothrombin complex concentrates with a "factor VIII bypassing activity". At the same time, the principle of action of factor Xa in such preparations is also discussed.
- the prothrombin-containing therapeutic composition produced according to EP 0 044 343-B1 is suitable for the treatment of coagulation factor inhibitors and contains an activated prothrombin complex in which the factors are partially activated.
- the proportion of factor VIIa is 8-80 units / ml.
- the factor IX concentration is in the range of 15 to 112 units / ml. Accordingly, the content of factor VIIa, based on factor IX, is 0.07-5.3 U factor VIIa / U factor IX.
- Vinazzer shows the difference between the preparations AUTOPLEX, which is produced according to EP 0 044 343, and FEIBA. As shown there, AUTOPLEX is characterized by the higher content of thrombin (factor Ha), measured in NIH units, compared to FEIBA (see Table 1, page 24).
- factor VIII preparations are their freedom from factor VIII.
- the fact that factor VIII is present in prothrombin complex preparations or in activated prothrombin complex preparations such as FEIBA results in patients with a functional factor VHI inhibitors that these inhibiting antibodies are boosted by re-administration of factor VIII, which temporarily even worsens the state of the inhibitor hemophilia.
- an immune-tolerant pharmaceutical prothrombin complex preparation containing factors II, IX, X and optionally VII with a low factor VIII antigen content is made available.
- the factor VIII antigen content of the preparation according to the invention is preferably less than 10%, in particular less than 5%.
- the factor VIII content is preferably less than 0.1 factor VIII.C antigen / E FEIBA.
- the factor VIII antigen content is even below 0.03 / E FEIBA, more preferably below 0.02 / E FEIBA and most preferably below the detection limit.
- the pharmaceutical preparation according to the invention contains paration at least the factors IXa, Xa and Vlla and has FEIB activity, thus shortens the clotting time of a factor VHI-deficient plasma with a functional inhibitor (see, for example, AT-B 350 726).
- a preparation according to the invention can be produced from plasma or a plasma fraction.
- the plasma fraction can be prepared from plasma, in particular plasma of human origin, by chromatographic treatment, precipitation or centrifugation, or the cryoprecipitate supernatant is used.
- the plasma fraction contains vitamin K-dependent factors such as factors of the prothrombin complex, but also protein S, C and / or Z are preferably contained.
- the preparation is free of phospholipids.
- the upper limit of phospholipids contained is preferably 0.1 nmol / E FEIBA (for determination see examples).
- This procedure includes the following steps:
- steps b and c or b, c and d are carried out as one process step.
- the plasma fraction used is preferably one with at least intermediate purity.
- a preparation with intermediate purity is to be understood as meaning a plasma fraction which is analogous to the definition of the intermediate purity of factor VHI preparations (see, for example, Wood Clive (ed.), Factor VIII: Purity and prophylaxis, Royal Society of Medicine).
- a conventional prothrombin complex factor preparation available on the market can also be used as the starting material, e.g. FEIBA S-TIM 4, IMMUNO or activated prothrombin complex.
- the carrier material is a material suitable for chromatography, filtration and / or nanofiltration. Filtration is, in particular, affinity or membrane filtration.
- a pre-cleaned material for example a material pre-cleaned by means of an anion exchanger
- readsorption can take place on a further carrier material, preferably on the same carrier material as used for the pre-cleaning, under changed conditions.
- the carrier material is a carrier material specific for factor VIII, in particular a matrix suitable for affinity chromatography.
- a matrix containing vWF is particularly preferably used.
- Factor VIII and optionally phospholipid are preferably adsorbed onto such a carrier material, while factors II, IX, X and optionally VII are not bound.
- the support material can also be a support material which is unspecific for factor VIII, for example a weak anion exchanger, for example a DEAE, TMAE or other anion exchanger which is sufficiently known from the prior art.
- a weak anion exchanger for example a DEAE, TMAE or other anion exchanger which is sufficiently known from the prior art.
- factor VIII and possibly phospholipids are adsorbed on the carrier material, while factors II, IX, X and optionally VII are not bound or vice versa.
- the carrier material has a higher affinity for the prothrombin complex than for factor VIII.
- factors II, IX, X and optionally VIII are adsorbed, while factor VIII and optionally phospholipids are eluted.
- the factor VIII can also be specifically inactivated and then, for example, no longer bind to the carrier material in this inactivated form.
- Such inactivation of factor VIII can be accomplished, for example, by dissociation using e.g. a chelating agent, by degradation, especially proteolytic degradation, e.g. by serine proteases such as thrombin or activated protein C, by binding affinity partners such as antibodies or peptides.
- All of the described process variants can also be carried out in the presence of a detergent, in particular a non-ionic detergent.
- a detergent in particular a non-ionic detergent.
- a polyether or a polysorbate is preferably used as detergent, in particular Tween or Triton is used. If detergent is present, it is removed or separated off in a preferred embodiment.
- a step for inactivating any pathogens which may be present in particular one selected from the group consisting of heat treatment, steam treatment, treatment with a solvent and / or treatment with a detergent, is provided.
- factor VIII inhibitor haemophilia A
- Such methods include physical and / or chemical treatments, such as various filtration methods (e.g. nano, slide or ultrafiltration), heat treatment, treatment with acid or alkali, treatment with detergent and / or organic solvent and treatment with UV light or laser -Light.
- various filtration methods e.g. nano, slide or ultrafiltration
- EP 0 197 554 discloses a method for depyrogenizing and inactivating viruses in a biological or pharmaceutical product, which involves treatment with a virus-inactivating and depyrogenizing agent, such as an amphiphilic substance and / or a solvent, on a solid phase to which the product is adsorbed. After this treatment, the virus-inactivating and depyrogenizing agent is separated from the solid phase, the adsorbed product is washed and finally eluted from the solid phase.
- a virus-inactivating and depyrogenizing agent such as an amphiphilic substance and / or a solvent
- EP 0 131 740 discloses the treatment of a protein-containing composition in a solution with organic solvents such as di- or trialkyl phosphates, optionally in the presence of a detergent (solvent / detergent treatment), as a result of which protein compositions can be obtained free of lipid-containing viruses .
- a heat treatment is known from AT-PS 402 151, in which a surfactant in a concentration of at least 1% by weight is added to a preparation in aqueous solution prior to heating.
- EP 0 083 999 Another method for reducing or suppressing undesired activities in biological or pharmaceutical products is known from EP 0 083 999. This is based on prolonged contact with a solution or suspension of a non-denaturing amphiphile. The depyrogenized product is treated with an ion exchanger to remove the amphiphile.
- a disadvantage of many of these methods known from the prior art is the frequent occurrence of activity losses in the labile proteins contained in the compositions to be treated, for example in blood proteins.
- proteins are inactivated to a relatively high degree. Protein breakdown can also lead to activation.
- factor VII is easily activated in a chromatographic purification due to autocatalytic processes to undesirable, because very unstable, factor VIIa.
- Another disadvantage lies in the high expenditure of time and equipment for many processes, which greatly reduces their practicability and therefore often makes their use on an industrial scale unsuitable.
- a method for the effective inactivation of pathogens in biological materials which is gentle on proteins, in particular for labile blood proteins, is to be used, which is also easily transferable to an industrial scale and can be carried out economically.
- the process for inactivating pathogens is intended to largely avoid degradation and possible activation of proteins which are sensitive to them.
- this material is incubated with a chemical agent, the incubation in the presence of an eluotropic salt corresponding to a NaCl concentration of at least 200 mmol / 1, preferably at least 300 mmol / 1, is made.
- Inactivating pathogens in solution has several advantages over treating an adsorbent. For example, the practicability of such a method in a homogeneous, single-phase system is higher and the validation of the inactivation step is easier. Also, the better accessibility of pathogens in a relatively homogeneous phase seems to increase the efficiency of the process step.
- the biological material preferably contains a human protein and is in particular plasma or a plasma fraction or comes from a cell culture.
- the biological material preferably contains a blood factor, such as factor XII, XI, VIII, V, from Willebrand factor or fibrinogen, in particular a vitamin K-dependent protein such as factor II, factor VII, factor IX, factor X, protein C, protein S or protein Z.
- the proteins can be present as individual factors, preferably in purified form, or in a complex mixture.
- the biological material contains at least one factor of the prothrombin complex and is in particular a fraction containing prothrombin complex or a material containing factor VII.
- the corresponding supernatant is used.
- the preparation according to the invention is preferably one with FEIB activity (Factor Eight Inhibitor Bypassing Activity), that is to say a preparation which is suitable for treating factor VHI inhibitor patients.
- FEIB activity Fractor Eight Inhibitor Bypassing Activity
- the material derived from a cell culture is preferably a material containing recombinantly produced blood factors, including factors of intrinsic or extrinsic coagulation, fibrinolysis, thrombolysis or their inhibitors, in particular vitamin K-dependent blood factors.
- Suitable cells are the cells customary for the expression of recombinant proteins, preferably mammalian cells, such as Vero, CHO or BHK cells.
- the corresponding proteins can be subjected directly to the process according to the invention for inactivating any pathogens present from the crude cell extract, but it can also be a pre-purified cell fraction.
- the chemical agent is, for example, a detergent (amphiphilic, surfactant), which is preferably contained in an amount of at least 1%, more preferably more than 5%, most preferably more than 10%;
- a detergent amphiphilic, surfactant
- other chemical agents can also be used according to the invention, in particular those for which e.g. a virucidal, bactericidal or depyrogenizing effect is already known, or mixtures of various chemical agents.
- a chemical that maintains the biological activity of the material to more than 50%, based on the activity before incubation. preferably at least 70%, especially more than 85%.
- Preservation of the biological activity means that the proteins contained in the biological material can perform the function naturally assigned to them or the various functions. This biological activity can then be determined and indicated depending on the type of protein, for example by means of a standardized chromogenic test or the antigen determination. If necessary, the chemical agent is separated after the incubation.
- a detergent is generally understood to be a synthetic, organic, surface-active substance.
- Nonionic detergent is preferably used in the method according to the invention.
- Nonionic surfactants such as polyethers, especially alkylphenol polyglycol ethers, include Products for the ethoxylation of fatty acids, fatty acid amides, fatty amines, fatty alcohols, amine oxides, fatty acid esters of polyalcohols and sugar esters.
- Such a surfactant does not have a denaturing effect on the proteins and is preferably selected from the group of polysorbate and triton.
- Tween ® for example, is used as the polysorbate.
- detergents are used as chemical agents, they are used according to a preferred embodiment without the addition of other agents, in particular without the addition of toxic organic substances or solvents, such as e.g. TNBP. This minimizes the risk of contamination.
- the biological material is incubated with a chemical agent in accordance with the method according to the invention.
- Incubation means bringing the biological material into contact with a solution, suspension or emulsion of a chemical agent for a sufficiently long time at a certain temperature to inactivate any pathogens or pyrogens that may be present.
- the contacting can be done, for example, simply by allowing the mixture to stand for a defined period of time.
- the incubation is carried out in the presence of an eluotropic salt.
- eluotropic salt is to be understood as the salt in a mixture with chemical agents or the salt in a complex composition, with the property of dissolving and / or displacing adsorbed substances from solid or liquid-like, also gel-like adsorbents.
- the eluotropic salt is preferably a desorbent, as is used in chromatographic processes.
- the adsorbed substance is generally sufficiently soluble in the presence of the eluotropic salt, ie conditions are preferably chosen which do not precipitate the biological material.
- the type and concentration of the salt or the composition is generally chosen depending on the adsorbent used.
- the eluting effect of a salt depends, for example, on the polarity of the solvent, e.g. in the order ethanol - acetone - methanol - water.
- the adsorbent can be a solid phase, in particular a matrix suitable for ion exchange chromatography.
- the composition containing the eluotropic salt can also contain further additives, for example further salts.
- the composition is preferably an aqueous composition with a pH in the range from 6.0 to 8.0, preferably around 7.0.
- sodium chloride is used as the eluotropic salt, but also other alkali or alkaline earth metal salts, including CaCl 2 .
- So-called chaotropes such as urea, rhodanide or guanidine, can also be used as eluotropic salts.
- the concentration of the salt is at least ⁇ 200 mmol / 1, preferably ⁇ 300 mmol / 1.
- the upper limit for the concentration used depends in particular on the solubility of the respective salt and is, for example, around 2 mol / l for NaCl. Chaotropic substances, such as urea, can even be used up to a concentration of 8 mol / 1.
- Incubation of the biological material with the chemical Agent is carried out for a period of time sufficient for the inactivation of any pathogens which may be present, preferably for a period between 10 minutes and 10 hours, most preferably between 1 hour and 5 hours.
- the time required for the method according to the invention can be determined in a preliminary experiment using model viruses such as HIV, Sindbis, FSME or hepatitis viruses.
- incubation is preferably carried out at room temperature, for example in a temperature range between 15 and 45 ° C., in particular between 20 and 30 ° C.
- the biological material is preferably adsorbed on a solid support, cleaned and the incubation is carried out immediately after elution of the cleaned material. Elution and incubation can be carried out consecutively, but they can also be carried out simultaneously.
- the incubation is carried out after a chromatographic purification of a biological material, the eluate being processed further, for example by centrifugation, filtration or other physical methods.
- the solid support is preferably a material suitable for chromatography, in particular a material suitable for ion exchange chromatography, hydrophobic chromatography or affinity chromatography.
- materials such as Sepharose ®, Superdex, Sephadex ®, Spherodex ®, ® Toyopearl, or inorganic materials such as hydroxyapatite can be used.
- anion exchange materials such as DEAESephacel ®, DEAE-Sephadex ®, DEAE-Sepharose ® CL6B, DEAE-Sepharose ® Fast Flow, QAE-Sephadex ®, Q-Sepharose ® Fast Flow Q-Sepharose ® High Performance , DEAE-Tris-Acryl, DEAE-Spherodex ® , Q-Hyper-D (available from Sepracor), DEAE-Toyopearl ®, QAE-Toyopearl ®, Fractogel ® EMD TMAE-Fractogel or other material may be used.
- anion exchange materials such as DEAESephacel ®, DEAE-Sephadex ®, DEAE-Sepharose ® CL6B, DEAE-Sepharose ® Fast Flow, QAE-Sephadex ®, Q-Sepharose ® Fast Flow Q-Sepharose ® High
- hydrophobic chromatographic materials are, for example, butyl Sepharose ®, octyl-Sepharose ®, phenyl Sepharose ®, ® Fractogel TSK-butyl, t-butyl HIC are called support or TSK gel Butyl Toyopearl ®.
- the biological material can be adsorbed onto the support and purified directly from a complex mixture, but the inactivation step can also be preceded or followed by further steps for cleaning the material, further chromatographic purification steps being preferred in the context of the present invention.
- Pathogens are inactivated by the method according to the invention. Pathogens also include fragments of e.g. Viruses, especially the isolated genome or its fragments, understood.
- the pathogens can be lipid-coated pathogens, e.g. Hepatitis B virus or non-lipid-enveloped pathogens, e.g. Hepatitis A virus.
- Virus inactivation methods are nowadays said to be effective if after application of the method to a sample of a biological material which has been mixed with a high dose of a test virus, for example HI virus or Sindbis virus as a model virus for hepatitis viruses, no viruses in the Sample can be detected and the virus titer has thus been reduced below the detection limit.
- Detection and quantification of nucleic acids can be carried out, for example, by means of a PCR method, as described in the ' AT-PS 401 062, or by direct titration.
- the so-called reduction factor is known, which is calculated from the decimal logarithm of the quotient of the initial and final virus titer after a single addition of test virus.
- the so-called total reduction factor is also known. It is calculated from the sum of the reduction factors from individual subsequent inactivation measures.
- Another independent step for inactivating or depleting pathogens is also preferably carried out. All methods known from the prior art can be used for this in order to minimize the risk of infection.
- filtration and / or heat treatment is carried out as a further step for inactivation or depletion.
- a nanofiltration is preferably carried out as the filtration.
- Preferred heat treatment is performed on the solid biological material, e.g. on a lyophilisate with controlled water content, for example a water content between 5 to 8% and a temperature between 50 and 80 ° C, as described in EP-0 159 311.
- a two-stage treatment with a detergent as chemical agent is provided.
- a detergent is used in an amount of at least 1%, preferably at least 5%, most preferably at least 10%.
- another detergent is used in an amount of at least 10%, preferably at least 12%, most preferably at least 14%.
- the detergent used can be the same for both stages, but different detergents can also be used.
- the combination of steps for virus inactivation can greatly reduce or exclude the risk of a virus infection after administration of a corresponding preparation.
- a chromatographically cleaned preparation is also provided, containing an autodynamically activatable blood factor with a proportion of activated blood factor of less than 50%, based on the hold on the activated and non-activated blood factor, preferably less than 40%, more preferably less than 30%, even more preferably less than 20%, further preferably less than 10%, most preferably less than 1%, and a detergent content .
- the preparation is a preparation containing a prothrombin complex with a factor VIIa activity of less than 50%, based on the content of activated and non-activated factor VII, preferably less than 10%, most preferably less than 1% .
- the detergent content of the preparation according to the invention is present in a pharmaceutically acceptable amount, preferably between 1% and the detection limit of the detergent.
- an autodynamically activatable blood factor is to be understood as a blood factor which can be activated autocatalytically, by surface contact or by processes such as, for example, chromatographic processes.
- a blood factor is one selected from the group factor VII, factor XII, factor XI and pre-kallikrein.
- the preparation is free from serine protease inhibitors, such as thrombin inhibitors, or the cofactors, e.g. Heparin.
- serine protease inhibitors such as thrombin inhibitors
- cofactors e.g. Heparin.
- the freedom from such substances is already given during a chromatographic process.
- the present invention therefore also relates to corresponding preparations obtainable by the process according to the invention.
- the preparation according to the invention may also contain further additives, for example substances with a stabilizing effect, such as amino acids.
- factor VIII antigen in FEIBA was carried out according to the method of Moritz B. al. (Thromb. Haemost. 1997, Suppl: 31). In this determination, a monoclonal antibody against the light chain of the factor VIII molecule as capture antibody and by means of a monoclonal antibody which is likewise directed against the light chain of the factor VIII molecule but against another epitope Detection antibody factor VIII selectively detected in FEIBA alongside other plasma proteins.
- Organically bound phosphate is made from the lyophilized powder of the FEIBA fraction by the method of Folch J. et al. (J. Biol.Chem. 1957,226: 497-509) by a solvent mixture consisting of chloroform, methanol in the ratio of 2 parts by volume of chloroform to 1 part by volume of methanol.
- the extract containing the entire phospholipid portion was then transferred to Teflon vessels and the organic solvents were evaporated under a stream of nitrogen. After adding a buffer (20 mM Tris HCl, 150 mM NaCl, pH 7.4) and oxisol reagent (from Merck), the Teflon vessels were sealed and digested at 160 ° for 5 h.
- the phosphate released by the digesting process was quantified photometrically as a molybdate complex by the method of Arnes B.N. (Methods in Enzymology 1966.8: 115-118).
- a CHO cell clone that produces recombinant von Willebrand factor is described in FEBS.Lett. 1994; 351: 345-348.
- the cell line was brought to co-expression of human furin by transfection with a vector coding for the cDNA human furin (van den Ouweland et al., Nucleic Acids Res. 1990; 18: 664).
- Such stable cell clones were fermented on a large scale in perfusion reactors on microcarriers. tiert (Blüml et al., in: Spier RE, Griffith JB, Berthold W, eds. Animal cell technology. Oxford, London: Butterworth-Heinemann, 1994: 267-269).
- the purification was carried out by a 2-stage chromatographic method according to Thromb.Haemost. 1995; 73: 1160.
- the fraction desorbed by elution with sodium chloride was obtained and buffered by gel filtration through Sephadex G25 (Pharmacia) in a buffer containing 20 mM Tris-HCl, 150 mM NaCl, pH 7.5.
- the preparation was then concentrated by ultraconcentration over an Amicon YM30 membrane (cut-off: 30,000 D) to a protein concentration of 3 mg / ml.
- the von Willebrand factor concentration in this preparation was 60 U vWF antigen / mg protein.
- the preparation of the recombinant von Willebrand factor was diluted to 1.5 mg / ml with a buffer containing 20 mM Tris-HCl, 150 mM NaCl, pH 7.5.
- a preactivated gel suitable for affinity chromatography (Actigel, ALD-Superflow, from Sterogene) was excessively prewashed with a buffer containing 20 mM Tris-HCl, 150 mM NaCl, pH 7.5.
- a volume part of the prewashed gel was mixed with 1.1 volume parts of the protein solution to be immobilized and then 0.15 volume parts of a solution of 0.1 M cyanoborohydride (NaCNBH3) in 0.1 M phosphate buffer, pH 7.0, was added.
- NaCNBH3 0.1 M cyanoborohydride
- the gel was suspended in this buffer by shaking and incubated for 16 hours at room temperature with further shaking.
- the gel was then placed on a sintered funnel with 10 times the volume of a buffer containing 20 mM Tris-HCl, 150 mM NaCl, pH 7.5 and with 5 times the volume of a buffer containing 20 mM Tris-HCl, 2 M NaCl, pH 7.5.
- the mixture was then again equilibrated with 5 parts by volume of the buffer, 20 mM Tris-HCl, 150 mM NaCl, pH 7.5 and the gel was transferred to a chromatographic column with a diameter dimension of 1: 4.
- a coupling rate of over 90% of the protein used could be determined by determining the protein concentration in the solutions of the incubation supernatant separated from the Willebrand factor solution and the affinity gel as well as the washing solutions on the sinter suction filter.
- EXAMPLE 4 Preparation of factor VIII-free prothrombin complex by contact with an affinity gel (currently the best way according to the applicant to carry out the invention):
- the pharmaceutical preparation FEIBA S-TIM4 IMMUNO (1000 units) was reconstituted with 20 ml of distilled water. When the freeze-dried powder had completely dissolved, the solution contained an active compound concentration of 50 units per ml. 10 ml of this solution were contacted with 100 mg of the immobilized von Willebrand factor described above and incubated for 1 h at room temperature with gentle shaking. The immobilizate was then removed by filtration through a sintered suction filter. The FEIBA solution obtained in the filtrate had an activity of 49 units FEIBA / ml. By binding factor VIII contained in the preparation to immobilized von Willebrand factor, factor VIII antigen in this preparation was below the detection limit.
- Example 5 Production of factor VHI-free activated prothrombin complex by readsorption on a non-specific carrier
- the buffer moist gel protein complex was now with 1.5 ml of a solution of 150 mg / ml TWEEN ® -80 and 30 mg / ml NaCl for 1 h at 26 ° C suspended.
- protein was desorbed together with the factors of the prothrombin complex and factor VIII.
- the suspension was then diluted by adding 6.5 ml of water and readsorbed for 1 h at room temperature, the prothrombin complex fraction being readsorbed again. At the same time, only a small part of the factor VIII contained in the protein fraction was readsorbed onto the gel.
- the gel / protein complex was then washed five times with 1 ml of a solution of 7 g / 1 NaCl in water, without detergent.
- the gel was treated with 0.7 ml of a solution of 30 g / 1 NaCl in water with stirring. The eluate was then dialyzed against distilled water, frozen and lyophilized. After reconstitution of the lyophilisate, the FEIB activity was determined in accordance with AT 350 726.
- the factor VIII antigen content was also determined.
- a conventionally produced FEIBA preparation as described in AT 350 726 served as a control.
- the preparation obtained by the described method had a factor VIII content reduced by a factor of 10 compared to the control.
- Example 6 Production of factor VIII-free and phospholipid-free activated prothrombin complex by readsorption on a non-specific carrier
- the buffer-moist gel protein complex was now with 1.5 ml of a solution of 1 mg / ml TWEEN ® -80 and 30 mg / ml NaCl for 1 hour at room temperature, suspended, wherein the protein fraction and non-specifically adsorbed impurities were desorbed. The gel was then separated off by filtration. The protein solution was then brought by further addition of TWEEN ® -80 to a detergent concentration of 150 mg / ml and then incubated for 1 hour at 40 ° C with stirring.
- the gel was treated with 0.7 ml of a solution of 30 g / 1 NaCl in water with stirring. The eluate was then dialyzed against distilled water, frozen and lyophilized. After reconstitution of the lyophilisate, the FEIB activity was determined in accordance with AT-B 350 726. The factor VIII antigen content and phospholipid were also determined as described.
- a conventionally produced FEIBA preparation which was obtained in accordance with AT 350 726, served as a control. The preparation obtained by the process described had a lower F VIII content than the control and was free of phospholipid. The analysis results are summarized in Table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0059497A AT405608B (en) | 1997-04-08 | 1997-04-08 | METHOD FOR INACTIVATING PATHOGENS, ESPECIALLY VIRUSES, IN A BIOLOGICAL MATERIAL |
AT59497 | 1997-04-08 | ||
AT159297A AT406824B (en) | 1997-09-19 | 1997-09-19 | Immunotolerant prothrombin complex preparation |
AT159297 | 1997-09-19 | ||
PCT/AT1998/000091 WO1998044942A1 (en) | 1997-04-08 | 1998-04-06 | Immunotolerant prothrombin complex preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0973544A1 true EP0973544A1 (en) | 2000-01-26 |
EP0973544B1 EP0973544B1 (en) | 2001-06-27 |
Family
ID=25593261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98913425A Expired - Lifetime EP0973544B1 (en) | 1997-04-08 | 1998-04-06 | Immunotolerant prothrombin complex preparation |
Country Status (14)
Country | Link |
---|---|
US (1) | US6358534B1 (en) |
EP (1) | EP0973544B1 (en) |
JP (1) | JP3976351B2 (en) |
AT (1) | ATE202483T1 (en) |
AU (1) | AU737566B2 (en) |
BR (1) | BR9807936A (en) |
CA (1) | CA2285935C (en) |
DE (1) | DE59800935D1 (en) |
DK (1) | DK0973544T3 (en) |
ES (1) | ES2160410T3 (en) |
NO (1) | NO994822L (en) |
PT (1) | PT973544E (en) |
SK (1) | SK139099A3 (en) |
WO (1) | WO1998044942A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATA159597A (en) * | 1997-09-19 | 2000-09-15 | Immuno Ag | PREPARATION FOR TREATING BLOOD COagulation disorders |
AT407484B (en) * | 1997-11-12 | 2001-03-26 | Bio Prod & Bio Eng Ag | MEDICINES FOR PROMOTING Wound Healing |
DE10012732A1 (en) | 2000-03-18 | 2001-09-20 | Aventis Behring Gmbh | Thrombin composition, for use as hemostatic or as a component of fibrin glues, comprises non-covalently bonded inhibitor for stabilization |
US20040185534A1 (en) * | 2000-10-02 | 2004-09-23 | Knudsen Ida Molgaard | Industrial-scale serum-free production of recombinant proteins in mammalian cells |
IL154880A0 (en) * | 2000-10-02 | 2003-10-31 | Novo Nordisk As | Method for the production of vitamin k-dependent proteins |
US20040185535A1 (en) * | 2003-03-21 | 2004-09-23 | Giles Wilson | Industrial-scale serum-free production of recombinant FVII in mammalian cells |
CA2460206C (en) * | 2001-10-02 | 2012-01-24 | Novo Nordisk Health Care Ag | Method for production of recombinant proteins in eukaryote cells |
US6989891B2 (en) | 2001-11-08 | 2006-01-24 | Optiscan Biomedical Corporation | Device and method for in vitro determination of analyte concentrations within body fluids |
RS52080B (en) * | 2002-07-23 | 2012-06-30 | Bio & Bio Licensing Sa | Pharmaceutically active substance preparations and drugs that are capable of generating thrombin and/or that contain thrombin |
EP1523327A1 (en) * | 2002-07-23 | 2005-04-20 | Bio-Products & Bio-Engineering Aktiengesellschaft | Pharmaceutical active ingredient preparations and medicaments that contain thrombin or have a thrombin-generating capacity |
US7364562B2 (en) * | 2005-10-06 | 2008-04-29 | Optiscan Biomedical Corp. | Anti-clotting apparatus and methods for fluid handling system |
EP2016402A2 (en) * | 2006-04-11 | 2009-01-21 | Optiscan Biomedical Corporation | Anti-clotting apparatus and methods for fluid handling system |
WO2008144575A2 (en) | 2007-05-18 | 2008-11-27 | Optiscan Biomedical Corporation | Fluid injection and safety system |
US20090176708A1 (en) * | 2007-12-27 | 2009-07-09 | Peter Turecek | Chemically modified factor ix |
US9488625B2 (en) | 2010-12-15 | 2016-11-08 | Baxalta GmbH | Purification of factor VIII using a conductivity gradient |
EP2867359B1 (en) * | 2012-06-29 | 2021-09-15 | EMD Millipore Corporation | Methods for inactivating viruses during a protein purification process |
IL230150A0 (en) | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One component fibrin glue comprising zymogens |
RU2559576C1 (en) * | 2014-06-09 | 2015-08-10 | Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ | Method of obtaining virus-safe complete prothrombin complex |
EP3205665A1 (en) * | 2016-02-11 | 2017-08-16 | Octapharma AG | Method of separating factor viii from blood products |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4286056A (en) * | 1980-01-28 | 1981-08-25 | Baxter Travenol Laboratories, Inc. | Method for making therapeutic enzyme compositions |
EP0044343B1 (en) | 1980-01-28 | 1984-08-22 | Baxter Travenol Laboratories, Inc. | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
AT368883B (en) | 1980-07-22 | 1982-11-25 | Immuno Ag | METHOD FOR PRODUCING A NEW HUMAN PROTEIN-BASED PREPARATION PROCESSING BLOOD |
US4412985A (en) | 1980-10-06 | 1983-11-01 | Edward Shanbrom | Depyrogenation process |
US4382083A (en) | 1981-06-25 | 1983-05-03 | Baxter Travenol Laboratories, Inc. | Therapeutic method for treating blood-clotting defects with factor VIIa |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4673733A (en) | 1985-04-11 | 1987-06-16 | Sudhish Chandra | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents |
US5156973A (en) | 1988-11-23 | 1992-10-20 | Edward Shanbrom | Antiviral blood sampling process and apparatus |
JP3145696B2 (en) | 1990-10-05 | 2001-03-12 | 日本ケミカルリサーチ株式会社 | Method for producing secretory immunoglobulin A preparation |
WO1993014791A2 (en) | 1992-01-27 | 1993-08-05 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
FI952196A0 (en) | 1995-05-08 | 1995-05-08 | Suomen Punainen Risti Veripalv | Immunoglobulin production |
DE19531637A1 (en) | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmaceutical composition for the treatment of blood coagulation disorders, method for the production thereof and their use |
US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
-
1998
- 1998-04-06 ES ES98913425T patent/ES2160410T3/en not_active Expired - Lifetime
- 1998-04-06 CA CA2285935A patent/CA2285935C/en not_active Expired - Fee Related
- 1998-04-06 DK DK98913425T patent/DK0973544T3/en active
- 1998-04-06 EP EP98913425A patent/EP0973544B1/en not_active Expired - Lifetime
- 1998-04-06 WO PCT/AT1998/000091 patent/WO1998044942A1/en not_active Application Discontinuation
- 1998-04-06 DE DE59800935T patent/DE59800935D1/en not_active Expired - Lifetime
- 1998-04-06 AT AT98913425T patent/ATE202483T1/en active
- 1998-04-06 SK SK1390-99A patent/SK139099A3/en unknown
- 1998-04-06 PT PT98913425T patent/PT973544E/en unknown
- 1998-04-06 JP JP54213398A patent/JP3976351B2/en not_active Expired - Lifetime
- 1998-04-06 AU AU68121/98A patent/AU737566B2/en not_active Expired
- 1998-04-06 BR BR9807936-0A patent/BR9807936A/en not_active Application Discontinuation
- 1998-04-06 US US09/402,582 patent/US6358534B1/en not_active Expired - Lifetime
-
1999
- 1999-10-04 NO NO994822A patent/NO994822L/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9844942A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU6812198A (en) | 1998-10-30 |
ES2160410T3 (en) | 2001-11-01 |
PT973544E (en) | 2001-12-28 |
CA2285935C (en) | 2011-01-18 |
NO994822L (en) | 1999-12-02 |
WO1998044942A1 (en) | 1998-10-15 |
DK0973544T3 (en) | 2001-10-15 |
EP0973544B1 (en) | 2001-06-27 |
JP3976351B2 (en) | 2007-09-19 |
DE59800935D1 (en) | 2001-08-02 |
CA2285935A1 (en) | 1998-10-15 |
ATE202483T1 (en) | 2001-07-15 |
BR9807936A (en) | 2000-02-22 |
JP2001524953A (en) | 2001-12-04 |
AU737566B2 (en) | 2001-08-23 |
SK139099A3 (en) | 2000-06-12 |
NO994822D0 (en) | 1999-10-04 |
US6358534B1 (en) | 2002-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0973544B1 (en) | Immunotolerant prothrombin complex preparation | |
AT408613B (en) | PHARMACEUTICAL FACTOR VII PREPARATION | |
AT398079B (en) | PREPARATION WITH THROMBINE ACTIVITY AND METHOD FOR THEIR PRODUCTION | |
EP0784632B1 (en) | Process for extracting high-purity von willebrand factor | |
DE69011136T3 (en) | Process for the preparation of a protein-containing composition. | |
DE69213421T2 (en) | Process for the preparation of an activated factor VII concentrate with a high purity | |
EP0765669A1 (en) | Pharmaceutical composition for the treatment of blood coagulation disorders, process to prepare it and its use | |
EP0674531A1 (en) | Process for preparing a virus-safe biological composition | |
EP0971958B1 (en) | Method for purifying factor viii/vwf complex by cation-exchange chromatography | |
EP0722344B1 (en) | Process for virus deactivation in the presence of a polyether and an agens | |
DE60311990T2 (en) | METHOD FOR PRODUCING A VIRUS-INACTIVED THROMBIN PREPARATION | |
EP0567448B1 (en) | Factor VIII preparation | |
AT409334B (en) | PHARMACEUTICAL PREPARATION CONTAINING VITAMIN K-DEPENDENT INDIVIDUAL FACTORS | |
DE3888571T2 (en) | Stabilization of biological and pharmaceutical products during the inactivation of viral and bacterial germs. | |
DE4434538C2 (en) | Virus inactivation method in the presence of a polyether and a chaotropic agent | |
EP0973543B1 (en) | Method for inactivating pathogens, especially viruses, in a biological material | |
AT406824B (en) | Immunotolerant prothrombin complex preparation | |
EP0841954B1 (en) | Method for the production of virussafe, therapeutic, biological preparations | |
AT402151B (en) | Process for the production of a virus-safe biological product | |
AT402892B (en) | Process for the production of a virus-safe biological product | |
EP0910629A1 (en) | Process for producing prothrombin as a basic antidote substance for natural and synthetic thrombin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991021 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: SI PAYMENT 19991015 |
|
17Q | First examination report despatched |
Effective date: 20000517 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: SI PAYMENT 19991015 |
|
REF | Corresponds to: |
Ref document number: 202483 Country of ref document: AT Date of ref document: 20010715 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER & CIE SA |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: GERMAN |
|
REF | Corresponds to: |
Ref document number: 59800935 Country of ref document: DE Date of ref document: 20010802 |
|
ITF | It: translation for a ep patent filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010928 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20010910 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2160410 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20010927 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20020430 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20030321 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20030502 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040406 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040430 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 59800935 Country of ref document: DE Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE Ref country code: DE Ref legal event code: R081 Ref document number: 59800935 Country of ref document: DE Owner name: BAXALTA GMBH, GLATTPARK, CH Free format text: FORMER OWNER: BAXTER AG, WIEN, AT Ref country code: DE Ref legal event code: R081 Ref document number: 59800935 Country of ref document: DE Owner name: BAXALTA INCORPORATED, BANNOCKBURN, US Free format text: FORMER OWNER: BAXTER AG, WIEN, AT |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: BAXTER EASTERN EUROPE VERTRIEBS GMBH; AT Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), VERANDERING VAN DE JURIDISCHE ENTITEIT; FORMER OWNER NAME: BAXTER AKTIENGESELLSCHAFT Effective date: 20160502 Ref country code: NL Ref legal event code: HC Owner name: BAXALTA INNOVATIONS GMBH; AT Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), VERANDERING VAN NAAM VAN DE EIGENAAR(S); FORMER OWNER NAME: BAXTER TRADING GMBH Effective date: 20160502 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: BAXALTA INCORPORATED; US Free format text: DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT; FORMER OWNER NAME: BAXTER AKTIENGESELLSCHAFT Effective date: 20160524 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20160519 AND 20160525 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TQ Owner name: BAXALTA INCORPORATED, US Effective date: 20160518 Ref country code: FR Ref legal event code: TQ Owner name: BAXALTA INNOVATIONS GMBH Effective date: 20160518 Ref country code: FR Ref legal event code: CJ Effective date: 20160518 Ref country code: FR Ref legal event code: CD Owner name: BAXALTA INNOVATIONS GMBH Effective date: 20160518 Ref country code: FR Ref legal event code: CD Owner name: BAXALTA INCORPORATED, US Effective date: 20160518 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 202483 Country of ref document: AT Kind code of ref document: T Owner name: BAXALTA GMBH, CH Effective date: 20160623 Ref country code: AT Ref legal event code: PC Ref document number: 202483 Country of ref document: AT Kind code of ref document: T Owner name: BAXALTA INCORPORATED, US Effective date: 20160623 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: BAXALTA GMBH Effective date: 20160823 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: BAXTER TRADING GMBH, AT Free format text: FORMER OWNER: BAXTER EASTERN EUROPE VERTRIEBS GMBH, AT Ref country code: CH Ref legal event code: PFA Owner name: BAXTER INNOVATIONS GMBH, AT Free format text: FORMER OWNER: BAXTER TRADING GMBH, AT Ref country code: CH Ref legal event code: PFA Owner name: BAXTER EASTERN EUROPE VERTRIEBS GMBH, AT Free format text: FORMER OWNER: BAXTER AKTIENGESELLSCHAFT, AT Ref country code: CH Ref legal event code: PFA Owner name: BAXALTA INNOVATIONS GMBH, AT Free format text: FORMER OWNER: BAXTER INNOVATIONS GMBH, AT |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: BAXALTA INCORPORATED, AT Free format text: FORMER OWNER: BAXALTA INNOVATIONS GMBH, AT Ref country code: CH Ref legal event code: NV Representative=s name: KELLER AND PARTNER PATENTANWAELTE AG, CH |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20170321 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20170426 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20170426 Year of fee payment: 20 Ref country code: GB Payment date: 20170427 Year of fee payment: 20 Ref country code: DE Payment date: 20170427 Year of fee payment: 20 Ref country code: IE Payment date: 20170428 Year of fee payment: 20 Ref country code: CH Payment date: 20170427 Year of fee payment: 20 Ref country code: DK Payment date: 20170425 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20170427 Year of fee payment: 20 Ref country code: FI Payment date: 20170427 Year of fee payment: 20 Ref country code: IT Payment date: 20170421 Year of fee payment: 20 Ref country code: SE Payment date: 20170427 Year of fee payment: 20 Ref country code: AT Payment date: 20170321 Year of fee payment: 20 Ref country code: ES Payment date: 20170503 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 59800935 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Effective date: 20180406 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20180405 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20180405 Ref country code: BE Ref legal event code: PD Owner name: BAXALTA GMBH; CH Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AFFECTATION / CESSION; FORMER OWNER NAME: BAXTER INNOVATIONS GMBH Effective date: 20160527 Ref country code: BE Ref legal event code: MK Effective date: 20180406 Ref country code: BE Ref legal event code: HC Owner name: BAXTER INNOVATIONS GMBH; AT Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT NOM PROPRIETAIRE; FORMER OWNER NAME: BAXTER AKTIENGESELLSCHAFT Effective date: 20150601 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 202483 Country of ref document: AT Kind code of ref document: T Effective date: 20180406 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20180405 Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20180406 Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20180417 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20180407 |